The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.

AstraZeneca (NASDAQ:AZN) announced Thursday that gefurulimab, its experimental injectable for generalized myasthenia gravis, ...

Imaavy (Nipocalimab-aahu ), a neonatal Fc receptor (FcRn) blocker, has been approved by the FDA for treatment of generalized myasthenia gravis in adults and adolescents with anti-acetylcholine ...

Luo L, Zhu X, Wen C, et al. Exploring the clinical significance of anti-acetylcholine receptor antibody titers, changes, and change rates in Myasthenia Gravis. Front Neurol. Published online ...

Cell types required for anti-acetylcholine receptor antibody synthesis by cultured thymocytes and blood lymphocytes in myasthenia gravis. Clinical and Experimental Immunology., 58:97-106.

Katyal N, Govindarajan R, Goyal N, et al. Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. Front Neurol. 2024;15:1378080. doi:10.3389/fneur ...

The clearest benefits of FcRn inhibition are seen in cases of myasthenia gravis caused by IgG autoantibodies to the acetylcholine receptor (Table 1); this observation is consistent with findings ...

ZILBRYSQ is a prescription medicine used to treat adults with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

The prevalence and incidence of gMG are increasing worldwide. 6 There are between 80,000 and 100,000 patients with myasthenia gravis in the U.S. 7,8 Approximately 85% of patients with myasthenia ...